# Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients with Mild to Moderately Active Ulcerative Colitis

> **NCT06488625** · PHASE2,PHASE3 · RECRUITING · sponsor: **University Hospital Schleswig-Holstein** · enrollment: 459 (estimated)

## Conditions studied

- Ulcerative Colitis, Unspecified

## Interventions

- **DRUG:** Low-Dose CICR-NAM
- **DRUG:** High-Dose CICR-NAM
- **DRUG:** 0 g/d CICR-NAM (blinded)
- **DRUG:** Open-Label

## Key facts

- **NCT ID:** NCT06488625
- **Lead sponsor:** University Hospital Schleswig-Holstein
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-12
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 459 (ESTIMATED)
- **Last updated:** 2024-11-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06488625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06488625, "Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients with Mild to Moderately Active Ulcerative Colitis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06488625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*